Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience.

Antiemetics / therapeutic use Dexamethasone / therapeutic use Hematopoietic Stem Cell Transplantation / adverse effects Humans Melphalan / adverse effects Multiple Myeloma / drug therapy Nausea / chemically induced Palonosetron / therapeutic use Pyridines Quality of Life Quinuclidines / therapeutic use Transplantation, Autologous Vomiting / chemically induced

ASCT Chemotherapy-induced nausea and vomiting (CINV) High-dose melphalan Multiple myeloma Netupitant/palonosetron (NEPA)

Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

ISSN: 1433-7339

Titre abrégé: Support Care Cancer

Pays: Germany

ID NLM: 9302957

Informations de publication

Date de publication:
Jan 2022

Historique:

received: 22 04 2021

accepted: 24 07 2021

pubmed: 5 8 2021

medline: 15 12 2021

entrez: 4 8 2021

Statut: ppublish

Résumé

Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent adverse events compromising quality of life (QoL) in patients undergoing autologous stem cell transplantation (ASCT). However, CINV prophylaxis is still lacking uniformity for high-dose melphalan (HDM), which is used to condition patients with multiple myeloma (MM). Netupitant/palonosetron (NEPA) is administered with dexamethasone (DEXA) for CINV prevention in several chemotherapy regimens. Our study aims to assess the efficacy of NEPA, without DEXA, in preventing CINV in 106 adult patients with MM receiving HDM and ASCT. All patients had antiemetic prophylaxis with multiple doses of NEPA 1 h before the start of conditioning and after 72 h and 120 h. A complete response (CR) was observed in 99 (93%) patients at 120 h (overall phase). The percentage of patients with complete control was 93%. The CR rate during the acute phase was 94% (n = 100). During the delayed phase, the CR rate was 95% (n = 101). Grade 1 nausea and vomiting were experienced by 82% and 12% of the patients, respectively. Grade 2 nausea was reported in 18% and vomiting in 10% of patients. Our results showed, for the first time, that NEPA, without DEXA, was a well-tolerated and effective antiemetic option for MM patients receiving HDM followed by ASCT.

Identifiants

DOI: 10.1007/s00520-021-06472-7 PMID: 34347181 PMC: PMC8331991

pubmed: 34347181

doi: 10.1007/s00520-021-06472-7

pii: 10.1007/s00520-021-06472-7

pmc: PMC8331991

doi:

Substances chimiques

Antiemetics 0

Pyridines 0

Quinuclidines 0

Palonosetron 5D06587D6R

netupitant 7732P08TIR

Dexamethasone 7S5I7G3JQL

Melphalan Q41OR9510P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

585-591

Informations de copyright

Références

Aapro M, Ruffo P, Panteri R, Costa S, Piovesana V (2018) Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey. Cancer Rep (Hoboken) 1:e1127

doi: 10.1002/cnr2.1127

Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333

doi: 10.1093/annonc/mdu101

Apolito V, Giaccone L, Ferrero S, Larocca A, Cavallo F, Coscia M, Beggiato E, Butera S, Martella F, Dainese C, Cetani G, Scaldaferri M, Cattel F, Boccadoro M, Ferrero D, Bruno B, Cerrano M (2020) Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Ann Hematol 99:2197–2199

doi: 10.1007/s00277-020-04180-6

Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO (2013) Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 19:344–356

doi: 10.1016/j.bbmt.2012.08.011

Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, Jaglowski S, Penza S, Andritsos LA, Devine SM (2014) Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Support Care Cancer 22:2911–2916

doi: 10.1007/s00520-014-2248-6

Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ, Medical Research Council Adult Leukaemia Working P (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883

doi: 10.1056/NEJMoa022340

Clark SM, Clemmons AB, Schaack L, Garren J, DeRemer DL, Kota VK (2016) Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. J Oncol Pharm Pract 22:416–422

doi: 10.1177/1078155215585190

D’Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM (2020) Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant 26:e177–e182

doi: 10.1016/j.bbmt.2020.04.013

Deauna-Limayo D, Aljitawi OS, Ganguly S, Abhyankar S, Wick JA, McGuirk JP (2014) Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: a pilot study. J Oncol Pharm Pract 20:263–269

doi: 10.1177/1078155213502103

Decramer M, Lacquet LM, Fagard R, Rogiers P (1994) Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 150:11–16

doi: 10.1164/ajrccm.150.1.8025735

Del Gaudio N, Di Costanzo A, Liu NQ, Conte L, Migliaccio A, Vermeulen M, Martens JHA, Stunnenberg HG, Nebbioso A, Altucci L (2019) BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition. Cell Death Dis 10:338

doi: 10.1038/s41419-019-1570-9

Di Costanzo A, Del Gaudio N, Conte L, Dell’Aversana C, Vermeulen M, de The H, Migliaccio A, Nebbioso A, Altucci L (2018) The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia. Oncogene 37:2559–2572

doi: 10.1038/s41388-018-0143-1

Di Costanzo A, Troiano A, di Martino O, Cacace A, Natale CF, Ventre M, Netti P, Caserta S, Pollice A, La Mantia G, Calabro V (2012) The p63 protein isoform DeltaNp63alpha modulates Y-box binding protein 1 in its subcellular distribution and regulation of cell survival and motility genes. J Biol Chem 287:30170–30180

doi: 10.1074/jbc.M112.349951

Di Renzo N, Musso M, Scime R, Cupri A, Perrone T, De Risi C, Pastore D, Guarini A, Mengarelli A, Benedetti F, Mazza P, Capria V, Chiusolo P, Cupelli L, Federico V, Bozzoli V, Messa AR, Codega P, Bonizzoni E, Specchia G (2020) Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. Bone Marrow Transplant 55:2114–2120

doi: 10.1038/s41409-020-0909-2

Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, Jordan K, Young A, Aapro M (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28:1260–1267

doi: 10.1093/annonc/mdx100

Giralt S (2010) 200 mg/m(2) melphalan–the gold standard for multiple myeloma. Nat Rev Clin Oncol 7:490–491

doi: 10.1038/nrclinonc.2010.104

Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW (2011) Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 22:939–946

doi: 10.1093/annonc/mdq457

Gonullu G, Demircan S, Demirag MK, Erdem D, Yucel I (2012) Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 20:1435–1439

doi: 10.1007/s00520-011-1226-5

Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340–1346

doi: 10.1093/annonc/mdu110

Isoda A, Saito R, Komatsu F, Negishi Y, Oosawa N, Ishikawa T, Miyazawa Y, Matsumoto M, Sawamura M, Manaka A (2017) Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: a phase II study. Int J Hematol 105:478–484

doi: 10.1007/s12185-016-2152-6

Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ (2011) The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant 46:784–789

doi: 10.1038/bmt.2010.205

Larsen J, Nordstrom G, Ljungman P, Gardulf A (2004) Symptom occurrence, symptom intensity, and symptom distress in patients undergoing high-dose chemotherapy with stem-cell transplantation. Cancer Nurs 27:55–64

doi: 10.1097/00002820-200401000-00007

Lopez-Jimenez J, Martin-Ballesteros E, Sureda A, Uralburu C, Lorenzo I, del Campo R, Fernandez C, Calbacho M, Garcia-Belmonte D, Fernandez G (2006) Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 91:84–91

pubmed: 16434375

Martino M, Olivieri A, Offidani M, Vigna E, Moscato T, Fedele R, Montanari M, Console G, Gentile M, Messina G, Irrera G, Morabito F (2013) Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opin Investig Drugs 22:619–634

doi: 10.1517/13543784.2013.788643

Mirabile A, Celio L, Magni M, Bonizzoni E, Gianni AM, Di Nicola M (2014) Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy. Future Oncol 10:2569–2578

doi: 10.2217/fon.14.132

Musso M, Scalone R, Crescimanno A, Bonanno V, Polizzi V, Porretto F, Bianchini C, Perrone T (2010) Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 45:123–127

doi: 10.1038/bmt.2009.114

Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting–two new agents. J Support Oncol 1:89–103

pubmed: 15352652

Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, Dolstra H, Lankester AC, Mohty M, Montoto S, Peffault de Latour R, Snowden JA, Styczynski J, Yakoub-Agha I, Kroger N, European Society for B, Marrow T (2020) The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transplant 55:1604–1613

doi: 10.1038/s41409-020-0826-4

Pastore D, Bruno B, Carluccio P, De Candia MS, Mammoliti S, Borghero C, Chierichini A, Pavan F, Casini M, Pini M, Nassi L, Greco R, Tambaro FP, Stefanoni P, Console G, Marchesi F, Facchini L, Mussetti A, Cimminiello M, Saglio F, Vincenti D, Falcioni S, Chiusolo P, Olivieri J, Natale A, Faraci M, Cesaro S, Marotta S, Proia A, Donnini I, Caravelli D, Zuffa E, Iori AP, Soncini E, Bozzoli V, Pisapia G, Scalone R, Villani O, Prete A, Ferrari A, Menconi M, Mancini G, Gigli F, Gargiulo G, Bruno B, Patriarca F, Bonifazi F (2020) Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. Ann Hematol 99:867–875

doi: 10.1007/s00277-020-03945-3

Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, Pidduck W, Bushehri A, Chow E, Jerzak KJ (2019) ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27:87–95

doi: 10.1007/s00520-018-4464-y

Schakman O, Gilson H, Thissen JP (2008) Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 197:1–10

doi: 10.1677/JOE-07-0606

Schmitt T, Goldschmidt H, Neben K, Freiberger A, Husing J, Gronkowski M, Thalheimer M, le Pelzl H, Mikus G, Burhenne J, Ho AD, Egerer G (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32:3413–3420

doi: 10.1200/JCO.2013.55.0095

Tendas A, Marchesi F, Mengarelli A, Annibali O, Tomarchio V, Saltarelli D, Chierichini A, Di Venanzio M, Sollazzo F, Piedimonte M, Cupelli L, Bruno A, De Angelis G, Delbono L, Niscola P, Perrotti AP, de Fabritiis P, Arcese W, Rome Transplant N (2019) Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. Support Care Cancer 27:793–803

doi: 10.1007/s00520-018-4594-2

Tendas A, Niscola P, Perrotti A, Dentamaro T, de Fabritiis P, Arcese W, Rome Transplant Network Quality of Life Working P (2015) Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need. Support Care Cancer 23:2211

doi: 10.1007/s00520-015-2711-z

Tendas A, Sollazzo F, Bruno A, Cupelli L, Niscola P, Pignatelli AC, Dentamaro T, de Fabritiis P, Arcese W (2012) Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant. Support Care Cancer 20:891–892

doi: 10.1007/s00520-012-1411-1

Trifilio S, Welles C, Seeger K, Mehta S, Fishman M, McGowan K, Strejcek K, Eiten E, Pirotte C, Lucier E, DeFrates S, Mehta J (2017) Olanzapine reduces chemotherapy-induced nausea and vomiting compared with aprepitant in myeloma patients receiving high-dose melphalan before stem cell transplantation: a retrospective study. Clin Lymphoma Myeloma Leuk 17:584–589

doi: 10.1016/j.clml.2017.06.012

Uchida M, Ikesue H, Miyamoto T, Kato K, Suetsugu K, Ichinose K, Hiraiwa H, Sakurai A, Takenaka K, Muta T, Iwasaki H, Teshima T, Shiratsuchi M, Egashira N, Akashi K, Oishi R (2013) Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. Biol Pharm Bull 36:819–824

doi: 10.1248/bpb.b12-01012